Erythropoietin Market in Japan 2015-2019

Description: About erythropoietin
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an excess of erythropoietin to maintain a normal level of red blood cells. When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs). These agents are similar to natural erythropoietin in structure and function. They can be produced by recombinant DNA technology and are used in the treatment of anemia resulting from renal disease, cancer, HIV, injuries, or neurological conditions.

The report forecasts the erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.

Covered in this report
In this report, the author the present scenario and growth prospects of the erythropoietin market in Japan for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.

The report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key vendors
- Chugai Pharmaceutical
- JCR Pharmaceuticals
- Kissei Pharmaceutical
- Kyowa Hakko Kirin

Other prominent vendors
- Eisai
- Otsuka
- Taiho Pharmaceutical
- Takeda

Market drivers
- Increased incidence of anemia due to illness
- For a full, detailed list, view the full report

Market challenges
- High cost of therapy
- For a full, detailed list, view the full report

Market trends
- Strategic alliances
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the Key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Biosimilars and biologics industry
Overview
Emerging role of biosimilars
Factors influencing biosimilars and biologics industry
Biosimilars: Business and pricing strategy
Biosimilars industry: Viewpoints of providers, payers, buyers, vendors, and regulatory bodies

PART 06: Japan: Country snapshot
Pharmaceutical industry in Japan
Biosimilars and biologics industry in Japan
Regulatory landscape
Healthcare reforms
Erythropoietin: Addressable market in Japan

PART 07: Global erythropoietin drugs market

PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 09: Market segmentation by application
End-stage renal disease
Cancer
HIV
Wounds and neural disease

PART 10: Market segmentation by product
First-generation erythropoietin formulation
Second-generation erythropoietin formulation
Biosimilars

PART 11: Market segmentation by end-user
Hospitals
Pharmacies

PART 12: Market drivers
Increased incidence of anemia
Reimbursement for erythropoietin preparations
Favorable growth opportunities

PART 13: Impact of drivers

PART 14: Market challenges
Complex manufacturing process
Complicated regulatory framework
Physician's reluctance to prescribe biosimilars

PART 15: Impact of drivers and challenges
PART 16: Market trends
Strategic alliances
Increased R&D of innovative molecule drugs
Focus on biosimilars

PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014

PART 18: Key vendor analysis
Chugai Pharmaceutical
JCR Pharmaceuticals
Kissei Pharmaceutical
Kyowa Hakko Kirin

PART 19: Appendix
List of abbreviations

PART 20: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Definition of biosimilars by organizations
Exhibit 03: Factors influencing biosimilars and biologics industry
Exhibit 04: Patent expiries of branded biologics
Exhibit 05: Impact of biosimilar cost savings on various sectors
Exhibit 06: Factors affecting success of biosimilars
Exhibit 07: Biosimilars industry: Point-of-view
Exhibit 08: Revenue of pharmaceuticals in Japan 2013 and 2020 ($ billions)
Exhibit 09: Pharmaceutical R&D expenditure in Japan 2000-2012 ($ millions)
Exhibit 10: Japan's percentage share in world imports of pharmaceuticals 2013
Exhibit 11: Japan's percentage share in world exports of pharmaceuticals 2013
Exhibit 12: Biosimilars approved by PMDA in Japan
Exhibit 13: Review process of biosimilars in Japan
Exhibit 14: Number of people with cancer in Japan 2010-2013
Exhibit 15: Incidence of cancers in Japan 2011
Exhibit 16: Approved erythropoietin biosimilars
Exhibit 17: Erythropoietin drugs market in Japan 2014-2019 ($ millions)
Exhibit 18: Five forces analysis
Exhibit 19: Erythropoietin drugs market in Japan by end-user 2014
Exhibit 20: Erythropoietin drugs market in Japan by product in hospitals 2014
Exhibit 21: Erythropoietin drugs market segmentation in Japan by product in retail pharmacies 2014
Exhibit 22: Number of people receiving dialysis in Japan 2008-2012
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Kyowa Hakko Kirin: YoY growth and revenue of NESP 2010-2014 ($ millions)
Exhibit 26: Kyowa Hakko Kirin: YoY growth and revenue of ESPO/NESP 2010-2012 ($ millions)
Exhibit 27: Chugai Pharmaceutical: YoY growth and revenue of Epogin 2010-2014 ($ millions)
Exhibit 28: Chugai Pharmaceutical: YoY growth and revenue of Mircera 2011-2014 ($ millions)
Exhibit 29: JCR Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection JCR 2011-2014 ($ millions)
Exhibit 30: Kissei Pharmaceuticals: YoY growth and revenue of Epoietin alfa BS injection (JCR) 2011-2014 ($ millions)
Exhibit 31: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
Exhibit 32: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 33: Kissei Pharmaceutical: Business segmentation by revenue 2015
Exhibit 34: Kissei Pharmaceutical: Business segmentation by revenue 2014 and 2015 ($ millions)
Exhibit 35: Kissei Pharmaceutical: Geographical segmentation by revenue 2015
Exhibit 36: Kyowa Hakko Kirin: Business segmentation by revenue 2014
Exhibit 37: Kyowa Hakko Kirin: Business segmentation by revenue 2013 and 2014
Exhibit 38: Kyowa Hakko Kirin: Geographical segmentation by revenue 2014
Ordering:

Order Online - http://www.researchandmarkets.com/reports/3420443/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Erythropoietin Market in Japan 2015-2019
Web Address: http://www.researchandmarkets.com/reports/3420443/
Office Code: SCH3G8XH

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________
Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp